Media | Contact us

About us
Protecting our tomorrow
A firm focus on vaccines stands at the core of everything we do.
READ MORE
At a glance
Our Leadership Team
Business Ethics
Sustainability
What we do
From R&D to manufacturing
We are focused on the research, development and manufacturing of innovative life-saving vaccines
READ MORE
Products
Pipeline
INVESTORS
Investors
We are committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
News
Events & Presentations

Annual Report 2024
Financials
Governance

Stock information
Analysts
Annual General Meeting
Shareholder Portal
FAQ
Careers
Careers
We offer a challenging international working environment in which job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Job Openings
Our Employees

Consensus

Bavarian Nordic collected consensus estimates prior to Q1 2025 results.

	Consensus
DKK, million	Q1 2025	2025
Total revenue	995	6,340
Public Preparedness (JYNNEOS/IMVANEX/IMVAMUNE)	453	3,606
Travel Health	500	2,530
Contract work	42	203
EBITDA margin	15%	29%

Number of participants: 4 analysts